A retrospective study of patients treated with Lutathera
Research type
Research Study
Full title
An international, non-interventional, post-authorization retrospective registry of patients treated with Lutathera® (lutetium (177Lu) oxodotreotide), to assess the efficacy and safety of Lutathera® for the treatment of pancreatic neuroendocrine tumors (pNETs).
IRAS ID
248950
Contact name
John Ramage
Contact email
Sponsor organisation
Advanced Accelerator Applications
Clinicaltrials.gov Identifier
NA, NA
Duration of Study in the UK
0 years, 6 months, 0 days
Research summary
This is an international, non-interventional, post-authorisation retrospective registry of patients diagnosed with pancreatic neuroendocrine tumors (pNETs) and treated with a drug called Lutathera.
The study will involve collecting and analysing patients' data from hospital medical records. The purpose is to find out how safe and effective Lutathera is. At the time of recruitment to the study, patients will also be asked to complete a short questionnaire about potential radiation exposure.
The population for this study is patients with pNETs who receive Lutathera. It is expected to recruit approximately 120 patients from 3 European countries: the UK, France and Spain.
REC name
West of Scotland REC 4
REC reference
18/WS/0116
Date of REC Opinion
12 Jul 2018
REC opinion
Further Information Favourable Opinion